QuestCap to Acquire 30% Interest in Glenco Medical

QuestCap (CSE:QSC) announced today that it has entered into an arm’s length share exchange agreement to acquire 30% of Glenco Medical Corp (“Glenco Medical”) – A private pre-revenue company founded and controlled by Dr. Glen Copeland.

QuestCap will issue a total of 12 million common shares in exchange for a 30% interest in Glenco Medical. Based QuestCap’s share price at the close of market on June 15, 2020, the deal is valued at $2.2M (CDN).

Glenco Medical is an injury treatment company providing effective and non-invasive remedies to alleviate musculoskeletal and inflammatory pain using wearable therapeutic technologies. Glenco Medical acts as the exclusive Canadian distributor of CareWear® wearable therapeutics class II low level light therapy device. Glenco Medical has extensive experience and orthopedic knowledge from treating sports injuries and garnering expertise establishing successful clinical operations, therapy protocols and outcome-based practices.

QuestCap Corporate Update Webinar

QuestCap is hosting a Corporate Update webinar on Wednesday, June 17 at 4 pm EST that will give the Company’s investment partners the opportunity to provide an update on their work. Select representatives from the MedQuest division will make short presentations on their progress and answer questions from shareholders.

QuestCap will be welcoming questions from participants, either through the registration form or during the webinar.

Registration Link https://us02web.zoom.us/webinar/register/WN_HRUqzh4mSuOP-dGeSSWeMA

Glenco Medical’s COVID-19 Standard for Safe Sport & Business

Glenco Medical recently established the COVID-19 Standard for Safe Sport, Industry, School Set and Retail (the “Standard”), through which it is developing and implementing protocols to safely return sports players, businesspeople, students, performers and shoppers to their respective professions and passions.

The Standard was designed by Dr. Glenn Copeland, it comprises medical screening protocols for individual health safety. The Screening will incorporate temperature and symptom checks in addition to serology testing for COVID-19 antibodies.

Doug Sommerville, CEO of QuestCap stated the following about the Glenco Medical acquisition:

“Glenco Medical’s extensive experience in working with professional sports leagues has built an expertise in the needs and challenges of keeping people healthy in these types of settings. They’ve been able to leverage that expertise to build custom protocols that we both anticipate will mitigate the spread of the virus in other settings where physical distancing is challenging.”

About the Standard

The Standard involves multi-phase protocols that ensures the safety of all participants and that mitigate the potential spread of coronavirus.  The key components of The Standard include:

  • COVID-19 testing and COVID-19 antibody testing.
  • Aggregation of individual test results and collaboration with governing bodies.
  • Enforcing medical recommendations and measures for recovery.
  • Digital ID verification, authentication and credential management.
  • Contact tracing in order to help identify, educate, and monitor individuals.

 

Questcap is a Market Awareness client of Capital 10X. 

0 0 vote
Article Rating

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.

Editor
Capital 10X gets down to the real money business, actionable financial insights for traders and investors. We analyze company earnings, interview management teams and help teach the fundamentals of financial analysis and options trading. Our mission is to hunt for genuine 10 baggers.
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments